As of 2025-07-01, the Intrinsic Value of ANI Pharmaceuticals Inc (ANIP) is 47.44 USD. This ANIP valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 65.25 USD, the upside of ANI Pharmaceuticals Inc is -27.30%.
The range of the Intrinsic Value is 14.68 - 264.59 USD
Based on its market price of 65.25 USD and our intrinsic valuation, ANI Pharmaceuticals Inc (ANIP) is overvalued by 27.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (98.45) - (37.53) | (45.51) | -169.7% |
| DCF (Growth 10y) | 14.68 - 264.59 | 47.44 | -27.3% |
| DCF (EBITDA 5y) | (4.06) - 1.60 | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | 15.41 - 29.00 | 21.11 | -67.6% |
| Fair Value | -0.66 - -0.66 | -0.66 | -101.01% |
| P/E | (1.15) - (1.26) | (1.30) | -102.0% |
| EV/EBITDA | (35.43) - (15.76) | (25.99) | -139.8% |
| EPV | 42.89 - 63.12 | 53.01 | -18.8% |
| DDM - Stable | (1.89) - (21.38) | (11.63) | -117.8% |
| DDM - Multi | 26.11 - 232.89 | 47.22 | -27.6% |
| Market Cap (mil) | 1,412.66 |
| Beta | 0.28 |
| Outstanding shares (mil) | 21.65 |
| Enterprise Value (mil) | 1,885.68 |
| Market risk premium | 4.60% |
| Cost of Equity | 6.71% |
| Cost of Debt | 7.53% |
| WACC | 6.56% |